Allstocks.com's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

» Allstocks.com's Bulletin Board » Hot Stocks Free for All ! » GNVC -$.89 » Post A Reply

Post A Reply
Login Name:
Password:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    
Message:

HTML is not enabled.
UBB Code™ is enabled.

 

Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?
Options


Disable Graemlins in this post.


 


T O P I C     R E V I E W
jdiddy  - posted
see DPTR link, called in .70's, much more to go, $1's today
 
jdiddy  - posted
1.02
 
jdiddy  - posted
1.08
 
jdizz  - posted
i was going to get into it, but it was to late
 
jdiddy  - posted
1.13
 
jdiddy  - posted
GNVC down to .68, this will be back above $1 soon. dont miss out.
 
jdiddy  - posted
quote:
Originally posted by jdiddy:
GNVC down to .68, this will be back above $1 soon. dont miss out.

at.70 , setting up
 
jdiddy  - posted
and BOOM , here we go .77's
 
jasbao  - posted
I got in at .68 last week, put my sell in for $1.00 a minute later. I can hold till then.
 
jdiddy  - posted
quote:
Originally posted by jdiddy:
GNVC down to .68, this will be back above $1 soon. dont miss out.

GNVC * .85 [Were Up]
 
jdiddy  - posted
.90 [Were Up] [Were Up]
 
Love the Market  - posted
This one's on it's way up - good news:

GenVec Expands Contract Supporting Malaria Vaccine ProgramLast update: 7/27/2009 7:55:00 AMGAITHERSBURG, Md., July 27, 2009 /PRNewswire-FirstCall via COMTEX/ -- Today GenVec, Inc. (GNVC) announced the expansion of an existing contract with the PATH Malaria Vaccine Initiative (MVI) to support the development of vaccines to fight malaria through MVI and USAID funding. This contract, valued at approximately $2 million, will continue a collaboration that began in 2004 and will initially support preclinical feasibility studies of novel adenovirus-based vaccines. Based on the results of the feasibility studies, GenVec, MVI, and USAID will contemplate preclinical and clinical development of these vaccines. "We appreciate the continued support from MVI and USAID and we look forward to advancing GenVec's vaccine technology through this collaboration," stated Dr. Joseph Bruder, head of GenVec's malaria program. About GenVec GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at and in the company's various filings with the Securities and Exchange Commission. On the Internet: Program for Appropriate Technology in Health (PATH): PATH Malaria Vaccine Initiative: USAID Malaria Vaccine Development Program: USAID: Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at . These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements. SOURCE GenVec, Inc. Copyright (C) 2009 PR Newswire. All rights reserved
 
Love the Market  - posted
MORE Grant Money!!

GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line DevelopmentLast update: 8/25/2009 7:25:00 AMGAITHERSBURG, Md., Aug 25, 2009 /PRNewswire-FirstCall via COMTEX/ -- GenVec, Inc. (GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology. Funds from this grant, valued at approximately $2.5 million over three years, will be used to support the development of novel cell lines capable of producing vaccine vectors based on different human serotype groups and encoding inhibitory antigens. "This important grant will support work to advance our cell line technology and enhance GenVec's ability to discover and develop new adenovector-based vaccines and therapeutics," said Dr. Doug Brough, GenVec's Executive Director of Vector Sciences. About GenVec GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at and in the company's various filings with the Securities and Exchange Commission. Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at . These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements. SOURCE GenVec, Inc. Copyright (C) 2009 PR Newswire. All rights reserved
 
Love the Market  - posted
Why didn't it hit $1.00 with THIS grant? It's so much bigger than the last one.....
 
Happy Valley  - posted
Nice little bit of news but don't lose site of the real news...

Next interim results for TNFerade PACT trial due out after 2/3's of events (184 deaths) have occured, prolly early 2010...Early results after 1/3 of events look good but this will be the real test...If after 2/3's of the events, TNFerade continues to show efficacy to the SOC arm alone, this will be a huge milestone...imo

Until then, trade the pops and build your stash...Easiest way to minimize your capital exposure going into clinical trial results or FDA decisions...jmo
 
Happy Valley  - posted
Big bids coming in...
 
Love the Market  - posted
WHY is this running on no news?? At least I can't find any on the wires. Did it take the world 24 hours to see yesterday's news?? WEIRD - but I'm happy!
 
jdiddy  - posted
FMD Vaccine Development
US - The Department of Homeland Security, Science and Technology Directorate, intends to award a contract on a sole-source basis to continue developing and retool production of cell lines and master seeds for foot and mouth disease vaccine.


The authority for this sole source award is FAR 6.302-1 - there is only one source that can provide these services and products to DHS. The contract will be awarded to Genvec, Inc. of Gaithersburg, Maryland. Genvec is the only entity capable of performing these services because it created and owns the intellectually property associated with cell lines and master seeds upon which the vaccine will be based.
 
Love the Market  - posted
jdiddy: Is this info part of a PR? I didn't see this anywhere.

TIA & Good Luck
 
Happy Valley  - posted
Crazy volume AH...

After Hours Last: $ .829 After Hours
High: $ .88
After Hours Volume: 2,415,264 After Hours
Low: $ .79

After Hours
Time (ET) After Hours
Price After Hours
Share Volume
17:08 $ .829 600
17:08 $ .829 2,250
17:08 $ .83 750
17:08 $ .83 270
17:07 $ .829 100
17:07 $ .829 4,500
17:06 $ .829 10,000
17:06 $ .829 5,000
17:06 $ .829 1,050
17:06 $ .83 100
17:06 $ .83 2,400
17:05 $ .83 100
17:05 $ .83 4,300
17:05 $ .83 3,100
17:05 $ .8299 1,000
17:05 $ .829 1,700
17:05 $ .8289 800
17:04 $ .83 100
17:04 $ .83 2,900
17:03 $ .829 1,300
17:03 $ .83 3,000
17:03 $ .8298 10,000
17:01 $ .83 1,000
17:01 $ .83 100
17:01 $ .83 1,000
17:01 $ .83 4,900
17:01 $ .829 12,000
17:01 $ .83 100
17:01 $ .83 1,000
17:01 $ .83 900
17:01 $ .83 100
17:01 $ .83 1,000
17:01 $ .83 8,900
17:01 $ .829 1,500
17:00 $ .829 400
17:00 $ .829 500
17:00 $ .829 6,000
17:00 $ .83 100
17:00 $ .83 1,000
17:00 $ .83 900
16:59 $ .8289 200
16:59 $ .8289 605
16:59 $ .83 100
16:59 $ .83 1,095
16:59 $ .83 100
16:59 $ .83 1,500
16:59 $ .829 4,000
16:59 $ .83 100
16:59 $ .83 5,000
16:59 $ .83 14,900
 
Love the Market  - posted
Got up to .86 with no news....Hmmmmm....
 
Love the Market  - posted
I can't find news anywhere - but it must be coming! Over 4 mil. vol. now and price hanging around .83-.84!! My only bright spot today!!

Maybe a run to close and big gap up? Good Luck!
 
Love the Market  - posted
Watch this on ABC News last Dec. about GenVec - TNF:

http://www.youtube.com/watch?v=R7q6IMOJ8-E
 
Love the Market  - posted
From Ya hoo thread:

GenVec, Inc. (GNVC) - Quote Info Search : in GenVec, Inc. (GNVC)Messages < Newer Topic | Older Topic >
Heere is the news: 15-Sep-09 02:38 pm I will give you the link later if you don't have one already.

SAME fund that bought 8% of CVM at 45c b4 CVM move just bought 8% of GNVC...gnvc at same govt meetin as CVM

coincidence?

Bam bought 8m shares of GNVC 2 weeks ago....LOVING GNVC now

-------------------
ROSTER:
http://www.csr.nih.gov/Roster_proto/meeting_roster.asp?stdate=9/8/2009&enddate=9 /8/2009&grcode=13&srg=IMMG&SRGDISPLAY=IMM-G&agsqnum=220994
 
Love the Market  - posted
THIS sure wasn't the news we were hoping for. Anyone think it will even matter, since they have 6 months to get over $1 and we may be there by 10am today?? :-)

GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance
GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance
Sep. 16, 2009 (PR Newswire) --

GAITHERSBURG, Md., Sept. 16 /PRNewswire-FirstCall/ -- On September 15, 2009, GenVec, Inc. (Nasdaq: GNVC) received a notice from The NASDAQ Stock Market stating that the minimum bid price of the Company's common stock was below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with Marketplace Rule 5450(a)(5). The notification letter has no effect at this time on the listing of the Company's common stock on The NASDAQ Global Market. GenVec's common stock will continue to trade on The NASDAQ Global Market under the symbol GNVC.


(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )


The notification letter states that GenVec will be afforded 180 calendar days, or until March 15, 2010, to regain compliance with the minimum closing bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least ten consecutive business days. NASDAQ may, in its discretion, require the Company's common stock to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.


If the Company does not regain compliance by March 15, 2010, NASDAQ will provide written notification to the Company that the Company's common stock will be delisted. At that time, the Company may appeal NASDAQ's delisting determination to a NASDAQ Listing Qualifications Panel. Alternatively, the Company could apply to transfer its common stock to The NASDAQ Capital Market if it satisfies all of the requirements, other than the minimum bid price requirement, for initial listing on The NASDAQ Capital Market set forth in Marketplace Rule 5505. If the Company were to elect to apply for such transfer and if it satisfies the applicable requirements and its application is approved, the Company would have an additional 180 days to regain compliance with the minimum bid price rule while listed on The NASDAQ Capital Market.


The Company intends to actively monitor the bid price for its common stock between now and March 15, 2010, and will consider available options to resolve the deficiency and regain compliance with the NASDAQ minimum bid price requirement.


About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.


Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding the Company's ability to comply with applicable listing standards, the ability to transfer to The NASDAQ Capital Market and actions by NASDAQ, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.


INVESTOR CONTACT: MEDIA CONTACT:GenVec, Inc. Tiberend Strategic Advisors, Inc.Danielle DiPirro Andrew Mielach(301) 944-1877 (212) 827-0020ddipirro*genvec.com amielach*tiberendstrategicadvisors.com


SOURCE GenVec, Inc.


Source: PR Newswire (September 16, 2009 - 8:30 AM EDT)

News by QuoteMedia
www.quotemedia.com
 
Love the Market  - posted
I took a nice profit on GNVC today - been holding it for MONTHS at .85 and I got taken out on a $1.00 GTC - went to 1.05 (on NO news)and I would of made another $200 - BUT - I'm so used to selling after losses this was a breath of freash air. Bought NEOM last week and trying to add more. Will buy back into GNVC IF it goes back to .80-ish.

The way it's been acting - I may start "playing" it like I should have all summer - I would have made 5 pretty pennies on it!
 
Love the Market  - posted
Missed seeing it drop this morning to .80 - already back over .85
 



Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share